Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab

Background Canakinumab (CAN) is indicated for the treatment of cryopyrin-associated periodic syndrome (CAPS) in patients ≥2 years of age [1]. However, patients may require treatment in infancy where CAN has not yet been studied. IL-1 inhibition has not affected antibody production after vaccination in healthy volunteers [2], but no data in patients receiving standard childhood vaccines are available.